Academic staff at First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Publications
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | Central Library of Charles University, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Standardized 18F-FDG PET/CT in patients with myeloma: joint recommendation of Czech Myeloma Group and Czech Society of Nuclear Medicine2023 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Standardization of PET/CT in patients with multiple myeloma – Joint recommendation of The Czech Myeloma Group and The Czech Society of Nuclear Medicine2023 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies2023 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data2022 | Central Library of Charles University, Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Limited efficacy of daratumumab in multiple myeloma with extramedullary disease2022 | Central Library of Charles University, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Identification of patients at high risk of secondary extramedullary multiple myeloma development2022 | Central Library of Charles University, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas2022 | Central Library of Charles University, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice2021 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...